Novo Nordisk, which has stumbled through a bit of a manufacturing hangover at a former Catalent production site it ...
Catalent’s sweeping workforce reductions within its Maryland gene therapy manufacturing operations were preceded by two FDA inspections in April that resulted in red flags from the agency, FDA fili | ...
The US Food and Drug Administration (FDA) has hit Philips with a warning letter after quality control shortcomings were uncovered at three of its medical device manufacturing sites. Issued on 9 ...
The FDA has made additional reports on inspections of ByHeart infant formula plants available. The company’s formula has been determined to be the source of at least 37 cases of infant botulism. The ...
The FDA has released documents showing that unsanitary conditions at a production plant for ByHeart infant formula and positive tests for pathogens have been going on since at least 2022. The company ...
Hosted on MSN
Shanghai Junshi Biosciences’ Subsidiary Passes FDA Inspection, Bolstering U.S. Market Expansion
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Shanghai Junshi Biosciences Co., Ltd.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback